Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REACH-2
  • Sponsors Eli Lilly; Eli Lilly Japan
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Overall Survival (OS)) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=292) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to the Eli Lilly media release, data from this and MONARCH 3 study investigating the impact of the addition of abemaciclib to fulvestrant or a nonsteroidal aromatase inhibitor (NSAI) on the start of subsequent chemotherapy will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top